Ametantrone

Ametantrone

SCHEMBL3344151

O=C1c2ccccc2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2B Q02880 1/20 1.00
LMNA P02545 6/20 0.68
MEN1 O00255 5/20 0.68
KMT2A Q03164 5/20 0.68
MAPK1 P28482 5/20 0.68
BLM P54132 4/20 0.68
SMN1; SMN2 Q16637 4/20 0.68
HTT P42858 4/20 0.68
NSD2 O96028 3/20 0.68
RECQL P46063 3/20 0.68
TDP1 Q9NUW8 3/20 0.68
NPC1 O15118 3/20 0.68
RAB9A P51151 3/20 0.68
USP2 O75604 2/20 0.68
TP53 P04637 2/20 0.68
MTOR P42345 2/20 0.68
EGFR P00533 2/20 0.68
TOP2A P11388 2/20 0.68
HIF1A Q16665 2/20 0.68
SLC22A2 O15244 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ametantrone SCHEMBL29723071 1.00 TOP2B (1.00) TOP2BLMNAMEN1KMT2AMAPK1
Hydrochloric Acid SCHEMBL11041980 0.98 TOP2B (0.97) TOP2BLMNAMEN1KMT2AMAPK1
SCHEMBL18567079 0.93 TOP2B (0.86) TOP2BLMNAMEN1KMT2AMAPK1
Ametantrone SCHEMBL29899532 0.93 TOP2B (0.86) TOP2BLMNAMEN1KMT2AMAPK1
Ametantrone SCHEMBL4022 0.93 TOP2B (0.86) TOP2BLMNAMEN1KMT2AMAPK1
Ametantrone SCHEMBL31237396 0.93 TOP2B (0.86) TOP2BLMNAMEN1KMT2AMAPK1
SCHEMBL15277979 0.91 TOP2B (0.83) TOP2BLMNAMEN1KMT2AMAPK1
SCHEMBL15271304 0.91 TOP2B (0.83) TOP2BLMNAMEN1KMT2AMAPK1
SCHEMBL1426702 0.90 TOP2B (0.81) TOP2BLMNAMEN1KMT2AMAPK1
SCHEMBL29357976 0.90 TOP2B (0.81) TOP2BLMNAMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9259380-B2 Means for dyeing and/or matting keratinic fibres containing novel 1,4 diaminoanthraquinone dyes HENKEL AG & CO. KGAA (DE) 2016-02-16 US claimed
US-20150007851-A1 MEANS FOR DYEING AND/OR MATTING KERATINIC FIBRES CONTAINING NOVEL 1,4 DIAMINOANTHRAQUINONE DYES HENKEL AG & CO. KGAA (DE) 2015-01-08 US claimed
US-20230240954-A1 USE OF ANTHRAQUINONE DYES AND OF FLUORESCENT DYES FOR DYEING KERATIN FIBRES, DYEING PROCESS AND COMPOSITION L'OREAL (FR) 2023-08-03 US disclosed
US-20220365074-A1 METHODS AND SYSTEMS FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSES USING pH ANALIZA, INC. (US) 2022-11-17 US disclosed
US-11401234-B2 Deuterated compounds and uses thereof OncoTherics Ventures Limited (GB) 2022-08-02 US disclosed
EP-3558235-B1 USE OF ANTHRAQUINONE DYES AND OF FLUORESCENT DYES FOR DYEING KERATIN FIBRES, DYEING PROCESS AND COMPOSITION OREAL (FR) 2021-09-08 EP disclosed
US-10928405-B2 Devices and methods for determining and/or isolating cells such as circulating cancer or fetal cells ANALIZA, INC. (US) 2021-02-23 US disclosed
EP-3702783-A1 METHODS FOR DETERMINING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS Analiza, Inc. (US) 2020-09-02 EP disclosed
EP-3702783-A1 METHODS FOR DETERMINING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS Analiza, Inc. (US) 2020-09-02 EP disclosed
US-20200270200-A1 DEUTERATED COMPOUNDS AND USES THEREOF OncoTherics Ventures Limited (GB) 2020-08-27 US disclosed
EP-3080341-B1 METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS ANALIZA INC (US) 2020-02-12 EP disclosed
US-5132327-A ANTI-CANCER COMPOUNDS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1992-07-21 US disclosed
WO-1991006540-A1 1,4-BIS(ALKYLAMINO)-2,3-DIAZA-ANTHRACENE-9,10-DIONES BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1991-05-16 WO disclosed
WO-1991005824-A1 ANTI-CANCER COMPOUNDS NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1991-05-02 WO disclosed
EP-0170290-B1 AMINO-ANTHRACENEDIONES-PLATINUM COMPLEXES USEFUL AS ANTI-CANCER COMPOUNDS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1990-06-13 EP disclosed
US-4732893-A ANTITUMOR AGENTS BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1988-03-22 US disclosed
US-4715993-A FROM SALTS, USING AMMONIA OR METHYLAMINE AMERICAN CYANAMID COMPANY (US) 1987-12-29 US disclosed
EP-0170290-A2 Amino-anthracenediones-platinum complexes useful as anti-cancer compounds BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1986-02-05 EP disclosed
US-4526788-A Polymeric[[(oxazolidinyl)alkyl]amino]anthraquinones AMERICAN CYANAMID COMPANY (US) 1985-07-02 US disclosed
EP-0122417-A2 Polymeric(((oxazolidinyl)alkyl)amino)anthraquinones AMERICAN CYANAMID COMPANY (US) 1984-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150007851-A1 MEANS FOR DYEING AND/OR MATTING KERATINIC FIBRES CONTAINING NOVEL 1,4 DIAMINOANTHRAQUINONE DYES KRT18, SAT1, KIF5A TOP2B 954/4885LMNA 920/4885MEN1 1473/4885
US-20230240954-A1 USE OF ANTHRAQUINONE DYES AND OF FLUORESCENT DYES FOR DYEING KERATIN FIBRES, DYEING PROCESS AND COMPOSITION KRT18, CUTA, KLK5 TOP2B 989/4885LMNA 266/4885MEN1 2794/4885
US-11401234-B2 Deuterated compounds and uses thereof HIF1AN, HIF1A, EGLN2 TOP2B 208/4885LMNA 1245/4885MEN1 2862/4885
US-20200270200-A1 DEUTERATED COMPOUNDS AND USES THEREOF HIF1AN, HIF1A, EGLN2 TOP2B 208/4885LMNA 1245/4885MEN1 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.